Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Asthma Challenge: Not Solved Yet

This article was originally published in Start Up

Executive Summary

Asthma represents one of the blockbuster markets in the pharmaceutical industry; sales of drugs from 10 companies amount to $14 billion each year. Yet despite the high-volume sales of asthma drugs, in 73% of patients the disease is poorly controlled. For pharmaceutical firms and start-ups, the complex, multifactorial disease offers tantalizing possibilities; it's an enormous, yet underserved market with many points of entry, mechanistically speaking.

You may also be interested in...



Start-Up News October 2006

Arbios Systems and Livercyte provide assistance for the failing liver, and Aperon Biosystems takes up the asthma challenge.

Topigen Pharmaceuticals Inc.

Topigen Pharmaceuticals Inc. plans to mount a full-scale attack on chronic respiratory ailments such as asthma, COPD and allergic rhinitis, with mRNA-interfering drugs that target multiple pathways. Its lead compound, for asthma, combines two antisense molecules to target at least eight different components of the inflammatory response.

airPharma

When it came time to build a pipeline, airPharma's founders turned to a product they knew well for their lead compound:a drug formerly marketed as Pumactant, for neonatal respiratory distress. This compound is an inhalable synthetic pulmonary surfactant. The symptoms of asthma have been associated with surfactant dysfunction.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel